An open-label, prospective study comparing efficacy, tolerability and cost of therapy of losartan with enalapril in stage 1 and stage 2 hypertension

Rubdeep Singh Bindra, Rajeev Mishra, Archana Vijayendranath, Sanjay K. Date


Background: Hypertension is a chronic disease which insidiously affects multiple systems in the body especially the cardiovascular and cerebrovascular systems. Also being a chronic disease the patient is required to take medications lifelong and this has financial implications. This study was attempted to evaluate drugs in two antihypertensive groups: Angiotensin II antagonist losartan v/s angiotensin converting enzyme inhibitor enalapril. Methods: A total of 100 patients as per the selection criteria were enrolled in the study and allocated randomly to either group A (losartan group) or group B (enalapril group). The study period was for 12 weeks, during which regular assessments were done - first on recruitment and then at 2nd week, 4th week, 8th week, and 12th week. The assessment parameters were diastolic, systolic pressures and pulse rate. Routine investigations were performed during the 1st visit and after 12 weeks of the study period.

Results: There were no significant differences between the treatment groups with respect to baseline patient demographic data and clinical characteristics like systolic blood pressure, diastolic blood pressure and heart rate. The cost benefit ratio and less adverse effects (cough), can be appreciated in group A (losartan group).

Conclusions: Losartan and enalapril were well tolerated after 12 weeks of treatment with notable tolerability advantages of losartan especially with respect to the respiratory system (cough). The cost of therapy for losartan group was almost half the cost of therapy for enalapril group and hence being cost effective. Thus, losartan could be preferred as a suitable alternative to enalapril as an antihypertensive agent.


Hypertension, Enalapril, Losartan

Full Text:



Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report Of The Joint National Committee On Prevention, Detection, Evaluation, And Treatment Of High Blood Pressure: the JNC 7 Report. JAMA 2003;289:2560-72.

Ramsay L, Williams B, Johnston G, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.

Ballermann BJ. Vasoactive peptides and the kidney. In: Brenner BM, Rector FC, editors. The kidney. Philadelphia: WB Saunders, 1991:510-83.

Friberg P. The renin-angiotensin system in neonatal rats: Induction of renal abnormality in response to ACE inhibition or angiotensin II antagonism. Kidney Int 1994;45:485-92.

Mitchell KD, Braam B, Navar LG. Hypertensinogenic mechanisms mediated by renal actions of the renin-angiotensin system. Hypertension 1992;19(1 Suppl):I18-27.

Carey RM, Howell NL, Jin XH, Siragy HM. Angiotensin type 2 receptor–mediated hypotension in angiotensin type 1 receptor–blocked rats. Hypertension 2001;38:1272-7.

Stoll M. The angiotensin AT2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-7.

Timmermann PB, Carini DJ, Chiu AT. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens 1991;4:275S-281S.

Burnier M, Waeber M, Brunner HR. Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects. J Hypertens 1995;13:S23-S28.

Gradmann AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-50.

Goldberg AI, Dunlay MC, Sweet CS, et al. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. J Am J Cardiol 1995;75:793-5.

Lacouciere Y, Lefebvre J, Nakhle G, et al. Association between cough and angiotensin converting enzyme inhibitors and angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 1994;12:S49-S53.

Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.

Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.

Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.

Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.

Cohn JN, Tognoni G, for the Val-HeFT Investigators. Effects of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2000;267:2672-6.

Ball SG, White WB. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers—a gap in evidence-based medicine. Am J Cardiol 2003;91:15-21.

Davis M, Poisal J, Chulis G, et al. Prescription drug coverage, utilization, and spending among Medicare beneficiaries. Health Aff (Millwood). 1999;18:231-43.

Nelson E, Arcuri K, Ikeda L, et al. Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens 1992;5:19A-20A.

Horiushi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-21.

Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin dependent mechanism. Hypertension 1998;31:349-55.

Birkenhager WH, de Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens 1999;17:873-81.

Staessen H et al. The diurnal BP profile. A population study. Am J Hypertens 1992;5:386–92.

Strutz F, Müller GA. Renal fibrogenesis and progression. In: Nielsen EG, Couser WC, editors. Immunologic renal diseases. Philadelphia, New York: Lipincott-Raven, 1997:705-26.